Published in ISRN Oncol on August 11, 2011
Beyond acute appendicitis: imaging of additional pathologies of the pediatric appendix. Pediatr Radiol (2012) 2.10
Signet-ring cell carcinoma of the appendix: a case report with an emphasis on sonographic findings. Ultrasonography (2015) 0.75
Mimicry of Appendicitis Symptomatology in Congenital Anomalies and Diseases of the Genitourinary System and Pregnancy. Curr Urol (2016) 0.75
The Management and Prognostic Prediction of Adenocarcinoma of Appendix. Sci Rep (2016) 0.75
Appendiceal Carcinoma with Krukenberg's Tumour Mimicking Primary Ovarian Cancer. J Clin Diagn Res (2013) 0.75
Intramucosal carcinoma of the appendix arising from traditional serrated adenoma. Case Rep Surg (2015) 0.75
Clinical experience in appendiceal neuroendocrine neoplasms. Contemp Oncol (Pozn) (2015) 0.75
Two concurrent appendiceal neoplasms in an elderly patient: A case report. Int J Surg Case Rep (2017) 0.75
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
Carcinoid tumors. N Engl J Med (1999) 6.44
An analysis of 8305 cases of carcinoid tumors. Cancer (1997) 6.24
Carcinoid tumors. An analysis of 2,837 cases. Cancer (1975) 4.62
71,000 HUMAN APPENDIX SPECIMENS. A FINAL REPORT, SUMMARIZING FORTY YEARS' STUDY. Am J Proctol (1963) 4.34
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med (2008) 4.04
Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer (2002) 3.89
Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum (1998) 3.81
Primary neoplasms of the appendix: radiologic spectrum of disease with pathologic correlation. Radiographics (2003) 3.59
Updated population-based review of carcinoid tumors. Ann Surg (2004) 3.21
The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg (1994) 2.59
Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg (2004) 2.33
Malignancies of the appendix: beyond case series reports. Dis Colon Rectum (2005) 2.02
Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum (1987) 1.96
Goblet cell carcinoid of the appendix. World J Surg Oncol (2005) 1.87
Carcinoid tumors. Am Fam Physician (2006) 1.58
Appendiceal ganglioneuromas and pheochromocytoma in neurofibromatosis type 1. AJR Am J Roentgenol (2000) 1.57
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology (1994) 1.43
Review article: current status of gastrointestinal carcinoids. Aliment Pharmacol Ther (1999) 1.35
The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Med Clin North Am (2005) 1.07
Neurofibromatosis of the appendix in von Recklinghausen's disease. A report of a case. Acta Pathol Microbiol Scand A (1975) 1.00
Adenocarcinoma of the appendix. Dis Colon Rectum (1985) 0.95
Giant appendix with diffuse ganglioneuromatosis. An unusual presentation of von Recklinghausen's disease. Eur J Surg (1992) 0.81
Primary malignant lymphoma of the appendix. Ulster Med J (1986) 0.80
Primary adenocarcinoma of the appendix. J R Soc Med (1996) 0.78
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39
Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57
Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol (2012) 1.56
Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43
Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30
Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17
The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design. J Clin Endocrinol Metab (2010) 1.11
Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06
Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04
Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03
Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02
Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02
Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99
Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98
Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96
IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96
Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96
Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93
FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91
Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90
Location-dependent ethnic differences in the risk of colorectal adenoma: a retrospective multiethnic study. J Clin Gastroenterol (2014) 0.90
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89
Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89
Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87
Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87
Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87
Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87
Early detection of pancreatic cancer. JOP (2012) 0.87
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86
Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86
Quality of life in patients with pancreatic cancer. JOP (2012) 0.86
Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86
The relationship of vitamin D status, smoking, and colorectal adenoma: a retrospective study in an ethnically diverse community. J Steroid Biochem Mol Biol (2012) 0.86
Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85
Germ cell cancer presenting as gastrointestinal bleeding and developing brain metastases: case report and review of the literature. Future Oncol (2012) 0.85
Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85
Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85
Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85
Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84
Eosinophilic gastrointestinal diseases: review and update. ISRN Gastroenterol (2012) 0.84
Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84
Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84
Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84
Advancements in the management of pancreatic cancer. JOP (2009) 0.83
Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83
Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83
First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83
PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83
Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83
Diabetes and pancreatic cancer. JOP (2014) 0.83
Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82
A case of gastrointestinal bleeding due to duodenal metastasis from a testicular choriocarcinoma. J Gastrointest Cancer (2013) 0.82
The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82
Role of anticoagulation in the management of pancreatic cancer. JOP (2009) 0.82
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol (2012) 0.82
Locally advanced pancreatic adenocarcinoma: update and progress. JOP (2012) 0.82
Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP (2009) 0.82
Biomarkers in neuroendocrine tumors. JOP (2013) 0.82
Elderly patients with pancreatic cancer. JOP (2014) 0.81
Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer (2009) 0.81
KRAS in pancreatic cancer. JOP (2014) 0.81
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. JOP (2014) 0.81
Novel treatment approaches for locally advanced pancreatic cancer. JOP (2014) 0.81
Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). JOP (2015) 0.81